403 related articles for article (PubMed ID: 30412748)
1. Compound Astragalus and Salvia miltiorrhiza extract inhibits hepatocellular carcinoma progression via miR-145/miR-21 mediated Smad3 phosphorylation.
Wu C; Chen W; Fang M; Boye A; Tao X; Xu Y; Hou S; Yang Y
J Ethnopharmacol; 2019 Mar; 231():98-112. PubMed ID: 30412748
[TBL] [Abstract][Full Text] [Related]
2. Compound Astragalus and Salvia miltiorrhiza extracts modulate MAPK-regulated TGF-β/Smad signaling in hepatocellular carcinoma by multi-target mechanism.
Boye A; Wu C; Jiang Y; Wang J; Wu J; Yang X; Yang Y
J Ethnopharmacol; 2015 Jul; 169():219-28. PubMed ID: 25934513
[TBL] [Abstract][Full Text] [Related]
3. Compound Astragalus and Salvia miltiorrhiza extracts suppress hepatocarcinogenesis by modulating transforming growth factor-β/Smad signaling.
Hu X; Rui W; Wu C; He S; Jiang J; Zhang X; Yang Y
J Gastroenterol Hepatol; 2014 Jun; 29(6):1284-91. PubMed ID: 24329763
[TBL] [Abstract][Full Text] [Related]
4. Compound Astragalus and Salvia miltiorrhiza extract suppresses hepatocellular carcinoma progression by inhibiting fibrosis and PAI-1 mRNA transcription.
Rui W; Xie L; Liu X; He S; Wu C; Zhang X; Zhang L; Yang Y
J Ethnopharmacol; 2014; 151(1):198-209. PubMed ID: 24247078
[TBL] [Abstract][Full Text] [Related]
5. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell invasion by modulating transforming growth factor-beta/Smad in HepG2 cell.
Liu X; Yang Y; Zhang X; Xu S; He S; Huang W; Roberts MS
J Gastroenterol Hepatol; 2010 Feb; 25(2):420-6. PubMed ID: 19793165
[TBL] [Abstract][Full Text] [Related]
6. Astragaloside IV inhibits hepatocellular carcinoma by continually suppressing the development of fibrosis and regulating pSmad3C/3L and Nrf2/HO-1 pathways.
Zhang C; Li L; Hou S; Shi Z; Xu W; Wang Q; He Y; Gong Y; Fang Z; Yang Y
J Ethnopharmacol; 2021 Oct; 279():114350. PubMed ID: 34157326
[TBL] [Abstract][Full Text] [Related]
7. Interaction of microRNA-21/145 and Smad3 domain-specific phosphorylation in hepatocellular carcinoma.
Wang JY; Fang M; Boye A; Wu C; Wu JJ; Ma Y; Hou S; Kan Y; Yang Y
Oncotarget; 2017 Oct; 8(49):84958-84973. PubMed ID: 29156696
[TBL] [Abstract][Full Text] [Related]
8. Compound
Wu C; Kan H; Hu M; Liu X; Boye A; Jiang Y; Wu J; Wang J; Yang X; Yang Y
Exp Ther Med; 2018 Aug; 16(2):1052-1060. PubMed ID: 30112050
[TBL] [Abstract][Full Text] [Related]
9. Smad3 C-terminal phosphorylation site mutation attenuates the hepatoprotective effect of salvianolic acid B against hepatocarcinogenesis.
Gong Y; Li D; Li L; Yang J; Ding H; Zhang C; Wen G; Wu C; Fang Z; Hou S; Yang Y
Food Chem Toxicol; 2021 Jan; 147():111912. PubMed ID: 33290806
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B.
Murata M; Matsuzaki K; Yoshida K; Sekimoto G; Tahashi Y; Mori S; Uemura Y; Sakaida N; Fujisawa J; Seki T; Kobayashi K; Yokote K; Koike K; Okazaki K
Hepatology; 2009 Apr; 49(4):1203-17. PubMed ID: 19263472
[TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV suppresses migration and invasion of TGF-β
Li L; Wang Q; He Y; Sun L; Yang Y; Pang X
Naunyn Schmiedebergs Arch Pharmacol; 2022 Apr; 395(4):397-405. PubMed ID: 35092472
[TBL] [Abstract][Full Text] [Related]
12. Salvianolic acid B exerts anti-liver fibrosis effects via inhibition of MAPK-mediated phospho-Smad2/3 at linker regions in vivo and in vitro.
Wu C; Chen W; Ding H; Li D; Wen G; Zhang C; Lu W; Chen M; Yang Y
Life Sci; 2019 Dec; 239():116881. PubMed ID: 31678285
[TBL] [Abstract][Full Text] [Related]
13. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
14. Compound Astragalus and Salvia miltiorrhiza Extract exerts anti-fibrosis by mediating TGF-beta/Smad signaling in myofibroblasts.
Yang Y; Yang S; Chen M; Zhang X; Zou Y; Zhang X
J Ethnopharmacol; 2008 Jul; 118(2):264-70. PubMed ID: 18502066
[TBL] [Abstract][Full Text] [Related]
15. Salvianolic acid B exerts an anti-hepatocellular carcinoma effect by regulating the Hippo/YAP pathway and promoting pSmad3L to pSmad3C simultaneously.
Xu W; Shi Z; Yu X; Xu Y; Chen Y; He Y; Gong Y; Huang C; Tan C; Yang Y
Eur J Pharmacol; 2023 Jan; 939():175423. PubMed ID: 36509132
[TBL] [Abstract][Full Text] [Related]
16. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
17. Amelioratory effects of astragaloside IV on hepatocarcinogenesis via Nrf2-mediated pSmad3C/3L transformation.
Fang Gong Y; Hou S; Xu JC; Chen Y; Zhu LL; Xu YY; Chen YQ; Li MM; Li LL; Yang JJ; Yang Y
Phytomedicine; 2023 Aug; 117():154903. PubMed ID: 37301185
[TBL] [Abstract][Full Text] [Related]
18. Compound Astragalus and Salvia miltiorrhiza extract inhibits cell proliferation, invasion and collagen synthesis in keloid fibroblasts by mediating transforming growth factor-β / Smad pathway.
He S; Yang Y; Liu X; Huang W; Zhang X; Yang S; Zhang X
Br J Dermatol; 2012 Mar; 166(3):564-74. PubMed ID: 21967214
[TBL] [Abstract][Full Text] [Related]
19. Phospho-Smad3L promotes progression of hepatocellular carcinoma through decreasing miR-140-5p level and stimulating epithelial-mesenchymal transition.
Hu X; Han D; Wang Y; Gu J; Wang X; Jiang Y; Yang Y; Liu J
Dig Liver Dis; 2021 Oct; 53(10):1343-1351. PubMed ID: 33775574
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of c-Jun NH2-terminal kinase switches Smad3 signaling from oncogenesis to tumor- suppression in rat hepatocellular carcinoma.
Nagata H; Hatano E; Tada M; Murata M; Kitamura K; Asechi H; Narita M; Yanagida A; Tamaki N; Yagi S; Ikai I; Matsuzaki K; Uemoto S
Hepatology; 2009 Jun; 49(6):1944-53. PubMed ID: 19418558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
